Literature DB >> 18630474

The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters.

George Giannopoulos1, Kitty Pavlakis, Aikaterini Parasi, Nikolaos Kavatzas, Dina Tiniakos, Antigoni Karakosta, Nikolaos Tzanakis, George Peros.   

Abstract

AIM: To investigate the expression of metalloproteinase (MMP) -2, MMP-9 and tissue inhibitor of MMP (TIMP) -2 in pancreatic ductal and ampullary carcinoma and to test the findings for correlation with angiogenesis and several clinicopathological parameters. PATIENTS AND METHODS: Paraffin sections from 32 pancreatic ductal adenocarcinomas and 17 ampullary carcinomas were assessed for the expression of MMP-2, MMP-9 and TIMP-2 by immunohistochemistry. Stromal and epithelial staining was evaluated separately. Moreover, sections stained immunohistochemically with anti-CD34 antibody were evaluated by image analysis for the quantification of microvessel density (MVD).
RESULTS: In pancreatic ductal adenocarcinoma, lower levels of glandular TIMP-2 were found in poorly differentiated tumors, while high glandular TIMP-2 expression was significantly associated with better survival. The age of the patients and the degree of differentiation of the tumor were identified as independent prognostic parameters. No relation was found between the expression of MMPs, TIMP or angiogenesis and the parameters under consideration. In ampullary adenocarcinoma, strong expression of glandular MMP-2 was associated with higher MVD values. Moreover, lymph vessel invasion was associated with higher stromal TIMP-2.
CONCLUSION: In pancreatic ductal adenocarcinoma, TIMP-2 may have a more crucial role in prognosis than MMP-2, MMP-9 or angiogenesis. In ampullary adenocarcinoma, MMP-2 expression correlated with MVD, supporting its postulated role in angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18630474

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

1.  Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer.

Authors:  Alexandra Mj Langers; Hein W Verspaget; Daniel W Hommes; Cornelis Fm Sier
Journal:  World J Gastrointest Oncol       Date:  2011-06-15

Review 2.  The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic.

Authors:  Thinzar M Lwin; Robert M Hoffman; Michael Bouvet
Journal:  Expert Rev Anticancer Ther       Date:  2018-05-28       Impact factor: 4.512

3.  Serum apolipoprotein C-II is prognostic for survival after pancreatic resection for adenocarcinoma.

Authors:  A Xue; J W Chang; L Chung; J Samra; T Hugh; A Gill; G Butturini; R C Baxter; R C Smith
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

4.  Relationship between single-nucleotide polymorphism of matrix metalloproteinase-2 gene and colorectal cancer and gastric cancer susceptibility: a meta-analysis.

Authors:  Zesheng Wu; Peng Jiang; Haider Zulqarnain; Hua Gao; Wenbin Zhang
Journal:  Onco Targets Ther       Date:  2015-04-16       Impact factor: 4.147

5.  Differential Expression of ADAM23, CDKN2A (P16), MMP14 and VIM Associated with Giant Cell Tumor of Bone.

Authors:  André Luis Giacometti Conceição; Erica Babeto; Natalia Maria Candido; Fernanda Craveiro Franco; Débora Aparecida Pires de Campos Zuccari; Jane Lopes Bonilha; José Antônio Cordeiro; Marilia Freitas Calmon; Paula Rahal
Journal:  J Cancer       Date:  2015-05-23       Impact factor: 4.207

6.  Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients.

Authors:  Magdalena Groblewska; Barbara Mroczko; Mariusz Gryko; Anna Pryczynicz; Katarzyna Guzińska-Ustymowicz; Bogusław Kędra; Andrzej Kemona; Maciej Szmitkowski
Journal:  Tumour Biol       Date:  2014-01-07

7.  Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.

Authors:  Maria Honkavuori-Toivola; Anne Talvensaari-Mattila; Ylermi Soini; Taina Turpeenniemi-Hujanen; Markku Santala
Journal:  Tumour Biol       Date:  2012-01-21

Review 8.  The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer.

Authors:  László Herszényi; István Hritz; Gábor Lakatos; Mária Zsófia Varga; Zsolt Tulassay
Journal:  Int J Mol Sci       Date:  2012-10-16       Impact factor: 5.923

9.  The estimation of metaloproteinases and their inhibitors blood levels in patients with pancreatic tumors.

Authors:  Jacek Śmigielski; Łukasz Piskorz; Renata Talar-Wojnarowska; Ewa Malecka-Panas; Sławomir Jabłoński; Marian Brocki
Journal:  World J Surg Oncol       Date:  2013-06-14       Impact factor: 2.754

10.  Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma.

Authors:  Katarzyna Jakubowska; Anna Pryczynicz; Joanna Januszewska; Iwona Sidorkiewicz; Andrzej Kemona; Andrzej Niewiński; Łukasz Lewczuk; Bogusław Kędra; Katarzyna Guzińska-Ustymowicz
Journal:  Dis Markers       Date:  2016-06-26       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.